These data, in addition to our in vitro data regarding a clear reduction of fibroplastic gene expression in response to YAP/TAZ inhibition, suggest YAP/TAZ may be an ideal target for treatment of VF fibrosis. The gene discussed is YAP1; the disease is ventricular fibrillation.